NEW GENERATION DES WITH NEW GENERATION POLYMERS. Prof. Dr. Rainer Wessely, Duisburg, Germany
|
|
- Cameron Lyons
- 5 years ago
- Views:
Transcription
1 NEW GENERATION DES WITH NEW GENERATION POLYMERS Prof. Dr. Rainer Wessely, Duisburg, Germany
2 Sousa J et al., JACC Cardioasv Interv years DES
3 NEXT DES BMS + DAPT DES DES + DAPT S A F E T Y BMS E F FI C A C Y Wessely R. C&V Update 2011
4 DES: complex interplay between components Wessely R, Nat Rev Cardiol, 2010
5 First generation DES SES PES ZES EES [Cypher] [Taxus] [Endeavor] [Xience/Promus] Earlier Later
6 Polymer Problem: No model to reliably and reproducibly test short and long term safety of polymers ( biocompatibility )
7 Current shortcomings of DESs Limited effectivity: Dosage, drug selection? bifurcated lesions; (insulin dependent) diabetics; ostial lesions Safety: (Late) stent thrombosis (particularly after discontinuation of antiplatelet therapy?) Polymer? Late restenosis: Polymer? Might be apparent in a yet undefined percentage of patients, especially with complex lesions
8 Polymer related issues mechanical biological
9 Polymer associated problems: not the end of the world
10 Polymer related issues Possible solution Avoid long term presence of polymer Avoid surface coating with polymer
11 Evidence and polymers: still much to learn
12 Even modern imaging tools are not sensitive enough to allow anatomical assessment of endothelialization resolution [ m] 1000 angioscopy 100 IVUS 1st gen OCT OFDI 10 Nagano M et al., Circulation. 2010;122:A
13 Physical presence and functional integrity: a whole new ballgame!
14 Functional vs. anatomical recovery: a different story? Pendyala LK et al., JACC Interv 2010
15 THE POLYMER necessary evil?
16 WHY might there be a current need for polymers on DES? Protection Protection of of non non intentional intentional drug drug release release during during stent stent delivery delivery and and placement placement Modulation, retardation of drug release, prevention of boost release Minimization Minimization of of cytotoxicity cytotoxicity of of drugs drugs with with small small therapeutic therapeutic window window
17 Time cascade for major pathophysiological events in ISR no polymer polymer
18 WHY is there a current need for polymers on DES? 0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1 0 CYPHER (n=202) Polymer-Free SES (n=201) 0,47 0, m In-Stent Late Loss (mm) ISAR-TEST 3: Polymer-free SES failed to meet non-inferiority vs CYPHER, despite >3-fold increase of drug dosage Mehilli J et al. Eur Heart J. 2008;29: Modulation of drug release is necessary to prevent boost release for optimized anti restenotic efficacy
19 Reducing adverse events precipitated by the polymer Limit presence of polymer to time necessary for drug delivery to counteract key events of restenosis (biodegradability) Avoid or limit polymer tissue contact Avoid mechanical disruption of polymeric coating Decrease amount and area coated by polymer relative to stent surface Anti inflammatory drug properties may counteract pro inflammatory (and therefore also pro thrombotic) polymer effects
20 Biodegradable polymers: application possible with any drug? Wessely R et al., Eur Heart J 2007
21 Biodegradable polymers: application possible with any drug? Paclitaxel Pimecrolimus 1,40 1,40 Late lumen loss [mm] 1,20 1,00 0,80 0,60 0,40 0,42 0,58 0,69 0,96 1,07 In-segment In-stent 0,20 0,00 PTX PTX+PMC PMC Verheye S et al., JACCI 2009
22 Parker T et al., Cur Pharmac Des 2010 Bioabsorbable polymer coatings for DES
23 Major DES platforms with biodegradable polymer DES System Platform Antiproliferative Agent Polymer BioMatrix (Biosensors Inc) S Stent (316 L) stainless steel stent with a strut thickness of inches (137 μm) Biolimus A9 ( 15.6 μg/mm of stent length) Polylactic acid (PLA) applied to the abluminal surface Cardiomind inches Sparrow (CardioMind, Inc) CardioMind self expandable Nitinol stent platform with strut thickness of inches (61 μm) Sirolimus ( 5.2 μg/mm of stent length) Polylactic acid (PLA)/Polylactic co glycolic acid (PLGA) block copolymer matrix ELIXIR DES program (Elixir Medical Corp) Cobalt chromium (Co Cr) stent with strut thickness of inches (81 μm) Novolimus ( 5 μg/mm of stent length) Myolimus ( 2 3 μg/mm of stent length Polyester based or polylactide based JACTAX (Boston Scientific Corp) Liberté (316 L) stainless steel stent with a strut thickness of inches (96.5 μm) Paclitaxel ( 0.6 μg/mm of stent length) D lactic polylactic acid (DLPLA) applied to the abluminal surface on premounted stent (no postcoating crimping distortion) NEVO (Cordis Corporation, Johnson & Johnson) Cobalt chromium (Co Cr) stent with strut thickness of inches (99 μm) Sirolimus ( 7.4 μg/mm of stent length) Polylactic co glycolic acid (PLGA) exclusively housed in reservoirs Sirolimus+EPC capture (OrbusNeich Medical Inc) OrbusNeich R stent (316L) stainless steel stent with a strut thickness of inches (101 μm) Sirolimus ( 5 μg/mm of stent length) SynBiosys polymer (2 bioabsorbable urethanelinked poly(ether ester) multiblock copolymers composed of glycolide (GA), lactide (LA), ϵ caprolactone (CL), and polyethylene glycol (PEG) pre polymer blocks) Supralimus and Supralimus Core (Sahajanand Medical Technologies Pvt Ltd) Millennium Matrix (316L) stainless steel stent with a strut thickness of inches (81 μm) Coronnium (L605) cobalt chromium stent with a strut thickness of inches (60 μm) Sirolimus ( 4.7 μg/mm of stent length) Poly L Lactide, 50/50 Poly DL Lactide co Glycolide and Polyvinyl Pyrrolidone Abizaid A et al., Circ Cardiovasc Interv 2010
24 New DES platforms with biodegradable polymer Nobori (Terumo) Biomatrix (Biosensors) JACTAX HD (Boston Scientific) ISAR Stent System (Translumina) NEVO (Cordis)
25 New DES platforms with biodegradable polymer: Biolimus A9 [LEADERS] Windecker S et al., Lancet 2008 [NOBORI CORE] Endothelial function in humans Hamilos MI et al., J Am Coll Cardiol 2008
26 New DES platforms with biodegradable polymer: JACTAX Grube E et al., JACC Interv 2010
27 New DES platforms with biodegradable polymer: ISAR Wessely R et al., ATVB 2005 [ISAR-TEST 4] Byrne et al., Eur Heart J 2009 Mehilli J et al., Eur Heart J 2008
28 Reservoir Technologie (Nevo) Recesses drug-polymer matrix into reservoirs Minimizes polymer contact with vessel wall Eliminates polymer-related friction Allows directional drug delivery Allows multi-drug delivery 2nd drug Wessely R. Nat Rev Cardiol, 2010
29 Polymer characteristics for the new NEVO DES platform SRL highly suited for biodegradable polymer delivery No polymer contact to vessel wall Polymer Absolute amount of polymer used only a fraction of current FDA approved DES Biodegradable polymer (PLGA) Stent design minimizes risk of polymer webbing, chibbing, etc.
30 Different polymers in comparison: preclinical data Severe 30 days 90 days Inflammation Moderate Mild 0 Xience Endeavor CYPHER BMS BioMatrix NEVO Taxus Price S et al. TCT 2009; poster presentation.
31 Spaulding C, presentation at EuroPCR 2011
32
33
34 NEVO RES I Nevo effective across all subgroups Spaulding C et al., Circ Cardiovasc Interv 2010
35 Take home messages The first decade of DESs has enabled interventional cardiology to safely and efficiently treat the vast majority of coronary lesions. Unlike paclitaxel, mtor inhibitors such as sirolimus can efficiently and safely be delivered with the use of a biodegradable polymer. Use of a biodegradable polymers is likely to improve safety of DES platforms, yet this has to be shown in appropriately sized RCTs. The potential use of multiple drugs, directional drug delivery, protected biodegradable polymer in low amounts and improved deliverability makes the upcoming generation of drug eluting stent platforms with reservoir technology an exciting novelty in the DES arena.
Taking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationThe DES Landscape in 2011
The DES Landscape in 2011 Future directions in drug-eluting stent design. BY JEFFREY S. KUNZ, MD, AND MARK A. TURCO, MD, FACC, FSCAI The development of bare-metal stents (BMS) in the late 1980s revolutionized
More informationDisclosure Eberhard Grube, M.D.
Disclosure Eberhard Grube, M.D. I disclose the following financial relationships: Consultant Sadra Medical, Core Valve, Biosensors, Orbus Neich, Cordis Johnson & Johnson, Boston Scientific, Mitralign,
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationBioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program
BioMatrix TM : The New Biodegradable Abluminally Coated DES BioMatrix TM Clinical Program T. Santoso Univ. of Indonesia Medical School Medistra Hospital Jakarta, Indonesia Biodegradable Abluminally Coated
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationDrug-eluting stents (DES)were primarily conceived to reduce
Advances in Interventional Cardiology New Drug-Eluting Stents An Overview on Biodegradable and Polymer-Free Next-Generation Stent Systems Alexandre Abizaid, MD, PhD; J. Ribamar Costa, Jr, MD Drug-eluting
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationSecond Generation Drug Eluting Stents: From Inhibition to Healing
Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke
More informationDrug-Eluting Stents for Coronary Artery Disease: A Review
Dublin Institute of Technology ARROW@DIT Articles School of Mechanical and Design Engineering 2010 Drug-Eluting Stents for Coronary Artery Disease: A Review David Martin Dublin Institute of Technology,
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More information生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 PCI milestones Pre Post Biodegradable polymer? 1 st revolution 1977 PTCA 2 nd revolution 1988 BMS 3 rd revolution 2000 DES Bioresorbable
More informationAre New DES Designs Safer?
cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 56 Are New DES Designs Safer? Changes in stent platform, polymer, and drug components have led to improved outcomes. BY ASHWANI SASTRY, MD, AND MITCHELL W. KRUCOFF,
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationCoroflex ISAR. Sirolimus Eluting Polymer-Free Coronary Stent System. Vascular Systems
Coroflex ISAR Sirolimus Eluting Polymer-Free Coronary Stent System Vascular Systems Coroflex ISAR Polymer-Free Drug Coating Complete Drug Release Sirolimus Established anti-inflammatory and anti-proliferative
More informationTailored bifurcation therapy
Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology
More informationYukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up
Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term
More informationBiodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial
Clinical trial report Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial Biodegradable polymer drug-eluting stent (DES) platforms have the
More informationThe Future Landscape of DES: New Stent Platforms, Drug Carriers, and Recent Experiences
13 th Angioplasty Summit 2008 TCT Asia Pacific The Future Landscape of DES: New Stent Platforms, Drug Carriers, and Recent Experiences Eberhard Grube MD FACC, FSCAI HELIOS Heart Center Siegburg, Germany
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
More informationReduction in Stent Thrombosis better tablets or better stents?
Reduction in Stent Thrombosis better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton MY CONFLICTS OF INTEREST ARE Speaker Fees/Honoraria/Travel Support Lilly/Daiichi
More informationYukon Choice PC Translumina trust is what counts
Sirolimus Eluting Coronary Stent System 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts DES with excellent long-term clinical outcome The Translumina PC drug-eluting
More informationNon stent based intracoronary drug delivery
Non stent based intracoronary drug delivery Dariusz Dudek Department of Interventional Cardiology Jagiellonian University, Krakow, Poland The European Association of Percutaneous Cardiovascular Interventions
More informationStent Pipeline. The unquestionable benefits brought by drugeluting COVER STORY. An update on absorbable polymers and stents.
Stent Pipeline An update on absorbable polymers and stents. BY ALEXANDRE ABIZAID, MD, PHD; ANDRE LIMA BRITO, MD; AND J. RIBAMAR COSTA, JR, MD The unquestionable benefits brought by drugeluting stents (DES)
More informationDevice and Clinical Program Highlights: SINOMED BuMA Stent
Device and Clinical Program Highlights: SINOMED BuMA Stent Runlin Gao, MD, FACC, FESC, FSCAI Fuwai Hospital, National Center for Cardiovascular Diseases, China CAMS, PUMC BuMA Supreme Platform and Pre-Clinical
More informationNext-generation drug-eluting stents tackle shortcomings of Cypher, Taxus February 7, 2006 Shelley Wood
Page 1 / 7 Sujet : Date : De : A : CC : Next-generation drug-eluting stents tackle shortcomings of Cypher, Taxus 06/05/2006 10:35:41 Paris, Madrid Evelyne Germe JPBEREGI jpberegi@chru-lille.fr Next-generation
More informationDevelopment Of DES Technology. HUO Yong,MD FACC Peking University First Hospital President-elect Chinese Society of Cardiology
Development Of DES Technology HUO Yong,MD FACC Peking University First Hospital President-elect Chinese Society of Cardiology Drug stents made in China Microport: Lepu: JW: Yinyi : Sinomed Yisheng Firebird
More informationAffiliation/Financial Relationship
The Next ERA: COMBO Dual Therapy Stent The Unmet Need Roxana Mehran, MD Mount Sinai i School of Medicine i Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have
More informationCoronary Stents: Past, Present and Future
Kardiologie Kardio Lunch 07.04.2016 Coronary Stents: Past, Present and Future Christoph Kaiser Universitätsspital Basel Rubin GS, The first balloon-expandable coronary stent, University of Queensland Press
More informationXIENCE Sierra INTRODUCING
INTRODUCING Sierra With the safety you ve always relied on and the deliverability you ve always wanted, choosing the right stent is now an easier decision. START 2017 Abbott. All rights reserved. AP2944678-OUS
More informationClinical Medicine Reviews in Vascular Health 2014:6
Open Access: Full open access to this and thousands of other papers at http://www.la-press.com. Clinical Medicine Reviews in Vascular Health Safety and Long-Term Efficacy of Sirolimus-Eluting Stents Ander
More informationBéla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment
Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional
More informationBiodegradable Polymer coated Drug Eluting Stents Versus Durable Polymer coated Drug Eluting Stents for Percutaneous Coronary Intervention
Biodegradable Polymer coated Drug Eluting Stents Versus Durable Polymer coated Drug Eluting Stents for Percutaneous Coronary Intervention Amos Levi, MD, Tamir Bental, MD, Abid R Assali, MD, Hanna Vaknin-Assa,
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationNext Generation Drug- eluting Stent : Will It Solve the Problem?
Next Generation Drug- eluting Stent : Will It Solve the Problem? Yangsoo Jang, M.D., Ph.D, FACC Severance Cardiovascular Hospital Yonsei University Healthcare System Commercially Available DES An Epidemic
More informationBiodegradable Polymer Drug- Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Biodegradable Polymer Drug- Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention A Pooled Analysis of Individual Patient Data from ISAR-TEST
More informationBiolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program
TCT Asia 2006 Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program Eberhard Grube MD FACC, FSCAI HELIS Heart Center Siegburg,
More informationThe Perfect Drug-Eluting Stent Goals for stent, polymer, and drug development.
The Perfect Drug-Eluting Stent Goals for stent, polymer, and drug development. BY TIM A. FISCHELL, MD, FACC, FSCAI; DWIGHT DISHMON, MD; ADAM ELHADDI, MD; SHADWAN ALSAFWAH, MD; AND SANTHOSH R. MANNEM, MD
More informationNovel stent and drug elution technologies
REVIEW Novel stent and drug elution technologies To address concerns of late and very late stent thrombosis associated with first generation drug-eluting stent technology, novel approaches are being tested
More informationBIOFLOW by Orsiro stents
BIOFLOW by stents Byeong-Keuk Kim, MD, PhD Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine Key Benefits Clinically proven
More informationDauer der doppelten Plättchenhemmung nach AMI / Stent
Dauer der doppelten Plättchenhemmung nach AMI / Stent Kardio-Lunch 04.06.2014 Christoph Kaiser Universitätsspital Basel Christoph.kaiser@usb.ch DAPT after Stenting 257 patients with PCI & stent: ASS &
More informationCOMPLEX CASES: LEFT MAIN
COMPLEX CASES: LEFT MAIN Resolute Onyx DES Together are trademarks of Medtronic. * Third-party brands are trademarks of For distribution only in markets where the Resolute Onyx coronary stent has been
More informationThe tailored solution for your bifurcation therapy
The tailored solution for your bifurcation therapy The tailored solution for your bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationΕνδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ
Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ DES Penetration -(2011) Source: Millenium Research Group Cordis has stopped manufacturing
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationContinuing Cardiology Education
Continuing Cardiology Education Stent selection for percutaneous coronary intervention P. D. Williams* & M. Awan James Cook University Hospital, Middlesbrough, United Kingdom Keywords Coronary artery disease,
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More informationSCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
More informationStents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.
Stents selection and optimal implantation: sizes, design, deployment Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationInterventional Cardiology
For reprint orders, please contact: reprints@futuremedicine.com Interventional Cardiology Bioengineering stents with proactive biocompatibility Percutaneous coronary intervention has revolutionized the
More informationCONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE
CONTEMPORARY DRUG-ELUTING STENTS AND VASCULAR RESPONSE Anwer Habib, 1 Hiroyoshi Mori, 2 Kazuyuki Yahagi, 2 *Aloke V. Finn 2,3 1. Parkview Heart Institute, Fort Wayne, Indiana, USA 2. CVPath Institute Inc.,
More informationProspective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results
Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results Stefan Verheye, MD PHD ZNA Middelheim Antwerp, Belgium Potential
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationInspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil
Stent Clinical Research Program Pedro A. Lemos MD PhD Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil All faculty disclosures are available on the CRF Events App and online
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationInterventional Cardiology
n Interventional Cardiology Indigenous stents: examining the clinical data on new technologies The availability and utilization of percutaneous coronary intervention in developing countries is limited
More informationREVOLUTION OF DRUG-ELUTING CORONARY STENTS: AN ANALYSIS OF MARKET LEADERS
REVOLUTION OF DRUG-ELUTING CORONARY STENTS: AN ANALYSIS OF MARKET LEADERS *Ashok S. Thakkar, 1 Bhargav A. Dave 2,3 1. Clinical Research, Meril Life Sciences Pvt., Ltd, Vapi, India 2. Manish Therapy Services,
More informationEVOLUTION OF DRUG-ELUTING STENT DRUG ELUTION PROFILE: IS A CRYSTALLINE DRUG FORM THE IDEAL SOLUTION?
EVOLUTION OF DRUG-ELUTING STENT DRUG ELUTION PROFILE: IS A CRYSTALLINE DRUG FORM THE IDEAL SOLUTION? *Giuseppe Sangiorgi, 1 Riccardo Colantonio, 2 Fabio De Luca 3 1. Department of Internal Medicine, Cardiac
More information1/22/2017. Ultimaster Clinical evidence. Hazem Khamis,MD,FACC October 6 University Egypt
Ultimaster Clinical evidence Hazem Khamis,MD,FACC October 6 University Egypt Vienna November 2012 1 2 IC-215303-AA JAN2014 5 of 25 IC-215303-AA JAN2014 6 of 25 1/22/2017 Key Elements of Stent for Complex
More informationSafety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationChallenges of in-stent Restenosis. The Balloon Approach
Challenges of in-stent Restenosis The Balloon Approach Bruno Scheller Klinische und Experimentelle Interventionelle Kardiologie, Universität des Saarlandes, Campus Homburg Klinik für Innere Medizin III,
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationDr Li Shu Kin FRCP (Lond, Edin & Glasg) FACC FHKAM. COS (Medicine) Pamela Youde Nethersole Eastern Hospital
Dr Li Shu Kin FRCP (Lond, Edin & Glasg) FACC FHKAM COS (Medicine) Pamela Youde Nethersole Eastern Hospital Des 1904-1979 1929 Andreas Gruentzig 1939-1985 1 st case in Sept1977 Overtook CABG as the most
More informationCoronary Stents: Past, Present, Future
Coronary Stents: Past, Present, Future Michael C Kim, MD FACC Director Cath Lab and IC Lenox Hill Heart and Vascular Institute Northwell Health IC-296208-AN DEC 2016 Page 1 1st-Generation DES was not ideal
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationFuture Developments in Coronary Stenting. Keith D Dawkins MD FRCP FACC Southampton University Hospital UK
Future Developments in Coronary Stenting Keith D Dawkins MD FRCP FACC Southampton University Hospital UK Conflicts of Interest Research Grant Support Boston Scientific Corporation Advisory Board/Consultant
More informationInterventional Cardiology חיים דננברג מערך הלב
Interventional Cardiology חיים דננברג מערך הלב הדסה עין-כרם History 1844- Claude Bernard. Introduced catheter through carotid artery of a horse into left ventricle to measure temperature. 1929- Werner
More informationInterventional cardiology has made great strides in
STEPHEN G. ELLIS, MD Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic HARIS RIAZ, MD Resident, Department of Internal Medicine, Cleveland Clinic Bioresorbable stents:
More informationBIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions
BIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions Johannes Waltenberger, MD, F.E.S.C. Uniklinik Münster Münster, Germany
More informationEberhard Grube MD FSCAI, FACC
SCAI 30 th Annual Scientific Sessions Orlando/Fla BMS and DES Thrombosis Differences among DES Eberhard Grube MD FSCAI, FACC HELIOS Heart Center Siegburg, Siegburg, Germany Stanford University, School
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More information2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES
2-year outcome of the 3-arm BIO-RESORT randomized trial in all-comer patients treated with contemporary DES Marlies M. Kok, MD Thoraxcentrum Twente, MST, Enschede, the Netherlands On behalf of the BIO-RESORT
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationABT 578 Elution from Phosphorylcholine: Zomaxx (Abbott)
ABT 578 Elution from Phosphorylcholine: Zomaxx (Abbott) Alan Yeung, MD Professor of Medicine, Interventional Cardiology Chair, Chief, Division of Cardiovascular Medicine (Clinical) Stanford University
More informationEvaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study
Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study OrbusNeich Dual Therapy COMBO Stent Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM FACC
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More informationAnalysis of trends and prospects regarding stents for human blood vessels
Lee et al. Biomaterials Research (2018) 22:8 https://doi.org/10.1186/s40824-018-0114-1 RESEARCH ARTICLE Open Access Analysis of trends and prospects regarding stents for human blood vessels Jeong Hee Lee
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationBioabsorbable Scaffolds: The Next Holy Grail?
Bioabsorbable Scaffolds: The Next Holy Grail? New Cardiovascular Horizons New Orleans, LA June 06, 2013 Lewis B. Schwartz, M.D., F.A.C.S. Vascular Surgery and Endovascular Therapy University of Chicago
More informationOCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT
OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT Substudy Carlo Di Mario, MD Peter Barlis, MD Evelyn Regar, MD Peter Juni, MD Patrick
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationDrug Eluting Stents: Update
Drug Eluting Stents: Update B. Berekoven Research Coordinator Department of Vascular Surgery St. Franziskus Hospital Münster Head: Univ.- Prof. Dr. G. Torsello baerbel.berekoven@sfh-muenster.de Disclosure
More informationBioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationDrug-eluting stent technology: progress beyond the polymer
European Heart Journal (2014) 35, 1991 1995 doi:10.1093/eurheartj/ehu224 EDITORIAL Drug-eluting stent technology: progress beyond the polymer Thomas Pilgrim and Stephan Windecker* Department of Cardiology,
More informationPrimary Endpoint Results of the EVOLVE Trial
Journal of the American College of Cardiology Vol. 59, No. 15, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.016
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical Centre & Monash University Melbourne, Australia
Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI,
More information